Vanda Pharmaceuticals (VNDA) came out with a quarterly loss of $0.50 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to loss of $0.07 per share a year ago.
Vanda Pharmaceuticals, Inc. (NASDAQ:VNDA ) Q4 2024 Earnings Conference Call February 13, 2025 4:30 PM ET Company Participants Kevin Moran - SVP, CFO & Treasurer Mihael Polymeropoulos - Founder, President, CEO & Chairman Conference Call Participants Charles Duncan - Cantor Fitzgerald Raghuram Selvaraju - H.C. Wainwright Andrew Tsai - Jefferies Operator Hello, and thank you for standing by.
Vanda Pharmaceuticals (VNDA) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.04 per share a year ago.
30 Jul 2025 (In 1 week) Date | | - Cons. EPS | - EPS |
29 Jul 2025 (In 1 week) Date | | - Cons. EPS | - EPS |
7 May 2025 Date | | - Cons. EPS | - EPS |
6 May 2025 Date | | - Cons. EPS | - EPS |
5 Feb 2025 Date | | - Cons. EPS | - EPS |
30 Jul 2025 (In 1 week) Date | | - Cons. EPS | - EPS |
29 Jul 2025 (In 1 week) Date | | - Cons. EPS | - EPS |
7 May 2025 Date | | - Cons. EPS | - EPS |
6 May 2025 Date | | - Cons. EPS | - EPS |
5 Feb 2025 Date | | - Cons. EPS | - EPS |
Biotechnology Industry | Healthcare Sector | Mihael H. Polymeropoulos CEO | XFRA Exchange | US9216591084 ISIN |
US Country | 368 Employees | - Last Dividend | - Last Split | 12 Apr 2006 IPO Date |
Vanda Pharmaceuticals Inc. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for addressing high unmet medical needs on a global scale. With a focus on conditions that affect sleep-wake disorders, schizophrenia, and a variety of other medical conditions, Vanda Pharmaceuticals seeks to improve the quality of life for patients worldwide. Since its incorporation in 2002, and headquartered in Washington, D.C., the company has made significant strides in bringing novel treatments to the market and continues to expand its robust pipeline of promising therapeutic candidates.